BeiGene
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 months.
- Recent price momentum is +8.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 1.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 49.7x | Better than 10% |
| Forward P/E | 40.1x | Better than 10% |
| Price / Sales | 6.8x | Better than 16% |
| P/E vs own 5-yr range | 78th pctl | Better than 28% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 87.5% | Better than 95% |
| Operating margin | 8.4% | Better than 46% |
| Net margin | 5.4% | Better than 45% |
| Return on equity | 7.5% | Better than 43% |
| Return on invested capital | 5.6% | Better than 48% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 4.4% | Better than 82% |
| 6-month return | 26.0% | Better than 87% |
| 12-month return (ex latest month) | 9.9% | Better than 46% |
| Distance below 52-week high | 8.0% | Better than 88% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.4x | Better than 77% |
| Debt to assets | 13.3% | Better than 65% |
| Interest coverage | 8.2x | Better than 69% |
| Free cash flow / net income | 300.1% | Better than 86% |
Analyst View B
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 17.6% | Better than 29% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 399.70
- Open
- 386.75
- Day range
- 385.00 - 399.76
- Avg price
- 393.43
- Volume
- 356.97K
- Turnover
- 140.44M
- Turnover ratei
- 0.44%
- Volume ratioi
- 1.45
- Amplitudei
- 3.69%
- 52-week rangei
- 253.95 - 424.73
Valuation
- P/Ei
- 154.52
- P/E (TTM)i
- 49.74
- P/Bi
- 7.67
- EPSi
- 2.53
- Book value / shi
- 50.96
- Net profit
- 288.99M
- Net assets
- 5.82B
Share structure
- Market cap
- 44.66B
- Float capi
- 31.65B
- Shares out
- 114.23M
- Float sharesi
- 80.95M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-02-03
8.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+70.85M net over the window
Short interest
- Shares short
- 1.60M
- % of floati
- 1.41%
- Days to coveri
- 4.37
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of BeiGene (ONC)?
BeiGene last traded at 390.94. This page shows a periodic quote snapshot. Check the displayed quote time.
What is BeiGene's market cap?
About 44.66B.
What is the P/E ratio of BeiGene?
The trailing twelve-month P/E is 49.74, above its own 5-year average of 28.27 — toward the top of its historical range (77.72% percentile). See the Valuation tab for the full history.
Does BeiGene pay a dividend?
BeiGene does not currently pay a regular dividend.
Is BeiGene a buy according to analysts?
The consensus of 12 analysts is a Buy rating, with an average 12-month price target of 459.87, which implies 17.6% upside from the current price. This is not investment advice.
What is BeiGene's StockVane Quant Rating?
The StockVane Momentum strategy currently rates BeiGene a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
BeiGene discussion 0 comments